1. Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection

5. What's So "Special" About HCV-GT3 Infection?

6. Why Talk About HIV/HCV Coinfection?

7. ALLY-3 Study

8. ALLY-3 (cont) Daclatasvir + Sofosbuvir for 12 Weeks

9. ALLY-3+ Study Daclatasvir + Sofosbuvir + Ribavirin for 12 or 16 Weeks in Patients With Advanced Fibrosis or Cirrhosis Infected With HCV-GT3

10. ALLY-3+ Study (cont)

11. ALLY-3+ Study, cont

12. ASTRAL-3 Study Sofosbuvir/Velpatasvir

13. ASTRAL-3 Study (cont)

14. ASTRAL-3 Study (cont)

15. Real-World Data How Effective and Safe Are These Regimens in Clinical Practice?

16. French Multicenter Compassionate Use Program Interim Analysis

17. French Multicenter Compassionate Use Program Interim Analysis (cont)

18. European Multicenter Compassionate Use Program Interim Analysis

19. Back to the Ribavirin Question

20. ALLY-2 Daclatasvir/Sofosbuvir

21. Rethinking HIV/HCV Coinfection Are the Results Really As Good As for HCV Monoinfection?

22. GECCO: Real-World Data Sofosbuvir/Ledipasvir for 8 Weeks

23. Sofosbuvir/Daclatasvir In Patients With HIV/HCV Coinfection and Advanced Liver Disease A Real-World Trial

24. C-EDGE Grazoprevir/Elbasvir for 12 Weeks in HCV-GT1, 4, 6

25. C-EDGE, cont Evaluated Outcomes In Monoinfection and Coinfection

26. C-EDGE, cont Grazoprevir/Elbasvir for 12 Weeks in HCV-GT1, 4, 6

27. Summary

28. Abbreviations

29. Abbreviations (cont)